S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
How Biden has already won 2024 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial

BioCryst Pharmaceuticals (BCRX) Earnings Date, Estimates & Call Transcripts

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)
Free bcrx Stock Alerts
$4.43
-0.07 (-1.56%)
(As of 05:21 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 1Estimated
Actual EPS
(Feb. 26)
-$0.28 Missed By -$0.04
Consensus EPS
(Feb. 26)
-$0.24
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

BCRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BCRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioCryst Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.19)($0.19)($0.19)
Q2 20241($0.16)($0.16)($0.16)
Q3 20241($0.13)($0.13)($0.13)
Q4 20241($0.14)($0.14)($0.14)
FY 20244($0.62)($0.62)($0.62)

BCRX Earnings Date and Information

BioCryst Pharmaceuticals last issued its earnings results on February 26th, 2024. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.04. The firm earned $93.40 million during the quarter, compared to analysts' expectations of $89.19 million. BioCryst Pharmaceuticals has generated ($1.18) earnings per share over the last year (($1.18) diluted earnings per share). Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.25) per share. BioCryst Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off prior year's report dates.

BioCryst Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/1/2024
Estimated)		------- 
2/26/2024Q4 2023($0.24)($0.28)($0.04)($0.25)$89.19 million$93.40 million
11/2/2023Q3 2023($0.25)($0.19)+$0.06($0.19)$86.54 million$86.74 million
8/3/2023Q2 2023($0.25)($0.24)+$0.01($0.08)$81.42 million$81.01 million    
5/3/2023Q1 2023($0.30)($0.28)+$0.02($0.28)$71.44 million$68.80 million    
2/21/2023Q4 2022($0.19)($0.38)($0.19)($0.38)$74.18 million$79.50 million    
11/1/2022Q3 2022($0.32)($0.23)+$0.09($0.23)$73.45 million$75.83 million
8/4/2022Q2 2022($0.36)($0.32)+$0.04($0.32)$63.92 million$65.53 million    
5/5/2022Q1 2022($0.39)($0.40)($0.01)($0.40)$50.59 million$49.92 million
2/23/2022Q4 2021($0.31)($0.40)($0.09)($0.70)$48.18 million$47.16 million
11/2/2021Q3 2021($0.29)($0.33)($0.04)($0.33)$37.75 million$40.99 million    
8/5/2021Q2 2021($0.22)($0.24)($0.02)($0.24)$31.37 million$49.96 million    
5/6/2021Q1 2021($0.26)($0.36)($0.10)($0.36)$12.80 million$19.06 million  

BioCryst Pharmaceuticals Earnings - Frequently Asked Questions

When is BioCryst Pharmaceuticals's earnings date?

BioCryst Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off last year's report dates. Learn more on BCRX's earnings history.

Did BioCryst Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) missed the analysts' consensus estimate of ($0.24) by $0.04 with a reported earnings per share (EPS) of ($0.28). Learn more on analysts' earnings estimate vs. BCRX's actual earnings.

How much revenue does BioCryst Pharmaceuticals generate each year?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded annual revenue of $331.41 million.

How much profit does BioCryst Pharmaceuticals generate each year?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded net income of -$226.54 million. BCRX has generated -$1.18 earnings per share over the last four quarters.

What is BioCryst Pharmaceuticals's EPS forecast for next year?

BioCryst Pharmaceuticals's earnings are expected to grow from ($0.68) per share to ($0.25) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:BCRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes
My biggest AI fear
Paradigm Press